BioGenetics Capital

BioGenetics Capital is a Singapore-based investment and holding company primarily focused on the life sciences and healthcare sectors. The firm gained prominence through its strategic association with BioGenetics Co., Ltd. (now Billions), a South Korean healthcare company that expanded into biopharmaceuticals in 2018. Through its investment portfolio, the company has been involved in the commercialization and development of oncology therapeutics, including the pan-HER inhibitor varlitinib and the DHODH inhibitor ASLAN003, in partnership with ASLAN Pharmaceuticals. Additionally, the group has engaged in the development of CAR-T cell therapies and novel treatments for Erbitux-resistant colon cancer. While the operating entity in Korea has since pivoted toward the entertainment industry, BioGenetics Capital remains an active holding entity within the regional healthcare investment landscape.